“…45 Previous studies have suggested that prolargin acts as a cell-type specific inhibitor of the NFκB pathway that impairs osteoclastogenesis. 45 In addition, increased NFκB activity has been shown to promote angiogenesis, invasion, metastasis, as well as chemoresistance in pancreatic cancer. 46 Thus, in VLTS, increased prolargin could potentially inhibit or diminish the NFκB signaling and thereby blocking tumorigenesis, invasion, angiogenesis and metastasis.…”